Edition:
India

HTG Molecular Diagnostics Inc (HTGM.OQ)

HTGM.OQ on NASDAQ Stock Exchange Capital Market

3.47USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$3.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
269,894
52-wk High
$5.82
52-wk Low
$1.59

Chart for

About

HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications... (more)

Overall

Beta: --
Market Cap(Mil.): $21.52
Shares Outstanding(Mil.): 11.45
Dividend: --
Yield (%): --

Financials

BRIEF-HTG Promotes John Lubniewski To President And Chief Operating Officer

* HTG PROMOTES JOHN LUBNIEWSKI TO PRESIDENT AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

17 Apr 2018

BRIEF-HTG Molecular Diagnostics Inc Says On March 30, 2018, Co And Qiagen Manchester Limited Entered Second Amendment Of First Statement Of Work

* HTG MOLECULAR DIAGNOSTICS INC - ON MARCH 30, 2018, CO AND QIAGEN MANCHESTER LIMITED ENTERED SECOND AMENDMENT OF FIRST STATEMENT OF WORK - SEC FILING

05 Apr 2018

BRIEF-Htg Molecular Diagnostics Secures Debt Facility With Midcap Financial

* HTG MOLECULAR DIAGNOSTICS SECURES DEBT FACILITY WITH MIDCAP FINANCIAL

27 Mar 2018

BRIEF-HTG Molecular Q4 Loss Per Share $0.15

* HTG MOLECULAR DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

23 Mar 2018

BRIEF-Stonepine Capital Management Reports 5.6 Pct Passive Stake In HTG Molecular Diagnostics

* STONEPINE CAPITAL MANAGEMENT LLC REPORTS A 5.6 PERCENT PASSIVE STAKE IN HTG MOLECULAR DIAGNOSTICS INC AS OF JANUARY 19 - SEC FILING Source text - http://bit.ly/2G2Dlxg Further company coverage:

23 Jan 2018

BRIEF-HTG Molecular Diagnostics Expects Q4 2017 Revenue of $7.6 Mln to $7.9 Mln- SEC Filing

* HTG MOLECULAR DIAGNOSTICS SAYS BASED ON CURRENTLY AVAILABLE INFORMATION EXPECTS Q4 2017 REVENUE BETWEEN $7.6 MILLION AND $7.9 MILLION - SEC FILING Source text: (http://bit.ly/2D99dyn) Further company coverage:

17 Jan 2018

BRIEF-HTG Molecular Announces Third Statement Of Work For New Clinical Assay Development Program

* HTG MOLECULAR ANNOUNCES THIRD STATEMENT OF WORK FOR NEW CLINICAL ASSAY DEVELOPMENT PROGRAM

16 Jan 2018

BRIEF-HTG Molecular, Illumina Agreed To Third Development Plan Under Parties' Amended & Restated Development & Supply Agreement

* HTG MOLECULAR DIAGNOSTICS - ON DEC 23, CO, ILLUMINA AGREED TO THIRD DEVELOPMENT PLAN UNDER PARTIES' AMENDED & RESTATED DEVELOPMENT & SUPPLY AGREEMENT

28 Dec 2017

BRIEF-HTG Molecular Diagnostics Expands Its Collaboration With Merck

* HTG MOLECULAR DIAGNOSTICS EXPANDS ITS COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY

27 Dec 2017

BRIEF-HTG Molecular Diagnostics reports third quarter earnings

* HTG Molecular Diagnostics reports 2017 third quarter earnings

08 Nov 2017

Earnings vs. Estimates